Hi locky27.
My understanding of the new R&D tax rebate is that a Company can now claim a Tax credit on any of it's expenses related to R&D. I would imagine that the costs in regard to the Cvac testing program would be considered an R&D activity. I don't see that there is a benefit as far as tax credits are concerned to shareholdersin filing their tax return. The only benefit I see to shareholders is that a shareholder who holds shares in a company undertaking R&D will benefit by the fact the Company can write off income etc against this R&D tax benefit, hence giving a "better" balance sheet for the end of year financial report.
Perhaps there is an accountant out there who could probably explain the R&D tax credit as it applies to PRR.
Thanks for your querry. I am an advocate of always asking questions to satisfy ones understanding of a particular matter.
Cheers
Good luck to all
- Forums
- ASX - By Stock
- IMM
- interesting article from mergermarket
interesting article from mergermarket, page-7
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M |
Open | High | Low | Value | Volume |
33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 211685 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 279000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 30940 | 0.320 |
3 | 63174 | 0.315 |
6 | 27370 | 0.310 |
2 | 2330 | 0.305 |
7 | 92922 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 250000 | 2 |
0.340 | 81685 | 3 |
0.345 | 207791 | 1 |
0.350 | 192258 | 4 |
0.355 | 169964 | 6 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online